Search





Search





Markets
/
Stocks
/
abbv
/

AbbVie Inc

ABBV

Add to Watchlist

256.910USD

+3.610+1.43%

Close 07-23 16:00（ET）Quotes delayed by 15 min

453.89BMarket Cap

126.46P/E TTM

AbbVie Inc

256.910

+3.610+1.43%

Profile Revenue Shareholders Corporate

Overview

Financials

Discussions

Analysis

Company

Profile Revenue Shareholders Corporate

More Details of AbbVie Inc Company

AbbVie Inc. is an American pharmaceutical firm based in North Chicago, Illinois. Its prominent products include Humira, which is approved for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis, and is administered through injection; Skyrizi, an interleukin-23 inhibitor also aimed at treating autoimmune disorders; Rinvoq, utilized for arthritis management; and Botox. Other significant offerings comprise Imbruvica for cancer treatment, Vraylar for schizophrenia and bipolar disorder, Venclexta for leukemia and lymphoma, and Mavyret for Hepatitis C treatment. The company is also dedicated to advancing therapies for additional conditions such as cancer, neurologic diseases, eye care, and cystic fibrosis.

AbbVie is ranked sixth among the largest biomedical companies by revenue and holds the 108th position on the Forbes Global 2000 list.

The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'

AbbVie Inc Info



Ticker SymbolABBV

Company nameAbbVie Inc

IPO dateJan 02, 2013

CEOMichael (Robert A)

Number of employees55000

Security typeOrdinary Share

Fiscal year-endJan 02

Address1 N Waukegan Rd

CityNORTH CHICAGO

Stock exchangeNASDAQ OMX NASDAQ Basic NYSE

CountryUnited States of America

Postal code60064

Phone18479327900

Websitehttps://www.abbvie.com/

Ticker SymbolABBV

IPO dateJan 02, 2013

CEOMichael (Robert A)

Company Executives of AbbVie Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

204.37K

+0.05%

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

135.75K

+0.82%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

55.37K

+5.41%

Mr. Edward J. (Ed) Rapp

Independent Director

45.96K

+2.43%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

39.58K

+2.82%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

Mr. Frederick H. (Rick) Waddell

Independent Director

30.08K

+3.72%

Ms. Melody B. Meyer

Independent Director

17.62K

+6.35%

Mr. Timothy J. Richmond

Chief Human Resources Officer, Executive Vice President

6.13K

-346.66%

Mr. Thomas J. (Tom) Falk

Independent Director

5.32K

+21.01%

Name

Name/Position

Position

Shareholding

Change

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

204.37K

+0.05%

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

135.75K

+0.82%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

55.37K

+5.41%

Mr. Edward J. (Ed) Rapp

Independent Director

45.96K

+2.43%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

39.58K

+2.82%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

FAQs

Who are the top five shareholders of AbbVie Inc?



The top five shareholders of AbbVie Inc are: Dr. Azita Saleki-Gerhardt, Ph.D.

How many institutions hold shares of AbbVie Inc (ABBV)?



As of 2026Q1, 5703 institutions hold shares of AbbVie Inc, with a combined market value of approximately 1.36B, accounting for 77.09% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 26641628.00.

What is the biggest source of revenue for AbbVie Inc?



In 2026Q1, the Immunology-SKYRIZI business generated the highest revenue for AbbVie Inc, amounting to 17.56B and accounting for 28.71% of total revenue.